Nexalis Therapeutics Ltd
NX1
Company Profile
Business description
Nexalis Therapeutics Ltd is an Australian clinical stage drug development company that is focused on developing therapies to address unmet medical needs in pain management and mental health sectors. Its pipeline includes three clinical drug candidates focused on treatment-resistant depression, breakthrough cancer pain, and panic disorder, each addressing areas of unmet medical need and potential commercial demand.
Contact
505 Little Collins Street
Level 9
MelbourneVIC3000
AUST: +61 390701221
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
Stocks News & Analysis
stocks
Does SpaceX’s sky-high valuation make sense?
SpaceX’s $1.5 trillion valuation looks expensive and risky, but not irrational.
stocks
ASX healthcare leader sees further cuts to fair value
Fiercer competition expected to squeeze margins.
stocks
Avoid this overpriced ASX share
This ASX share is 84% overvalued and lacks a sustainable competitive advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.80 | 44.30 | 0.50% |
| CAC 40 | 8,041.81 | 126.45 | 1.60% |
| DAX 40 | 23,640.03 | 328.60 | -1.37% |
| Dow JONES (US) | 47,417.27 | 289.24 | -0.61% |
| FTSE 100 | 10,353.77 | 58.47 | -0.56% |
| HKSE | 25,898.76 | 490.30 | 1.93% |
| NASDAQ | 22,716.13 | 19.03 | 0.08% |
| Nikkei 225 | 55,025.37 | 776.98 | 1.43% |
| NZX 50 Index | 13,293.13 | 194.30 | 1.48% |
| S&P 500 | 6,775.80 | 5.68 | -0.08% |
| S&P/ASX 200 | 8,743.50 | 39.10 | 0.45% |
| SSE Composite Index | 4,133.43 | 10.29 | 0.25% |